Lexaria Bioscience Corp. (LEXX) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Lexaria Bioscience Corp. (LEXX) Bundle
Whether you're an investor or analyst, this (LEXX) DCF Calculator is your go-to resource for accurate valuation. Equipped with real data from Lexaria Bioscience Corp., you can adjust forecasts and observe the effects in real time.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .4 | .7 | .3 | .2 | .5 | .6 | .8 | 1.0 | 1.2 | 1.6 |
| Revenue Growth, % | 0 | 87.95 | -64.66 | -11.43 | 105.24 | 27.96 | 27.96 | 27.96 | 27.96 | 27.96 |
| EBITDA | -4.0 | -5.6 | -6.5 | -6.4 | -5.7 | -.6 | -.8 | -1.0 | -1.2 | -1.6 |
| EBITDA, % | -1040.9 | -771.39 | -2551.45 | -2824.23 | -1222.75 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .1 | .1 | .1 | .1 | .1 | .2 | .3 | .4 | .5 | .6 |
| Depreciation, % | 37.99 | 20.42 | 57.52 | 64.28 | 16.4 | 39.32 | 39.32 | 39.32 | 39.32 | 39.32 |
| EBIT | -4.1 | -5.7 | -6.7 | -6.5 | -5.8 | -.6 | -.8 | -1.0 | -1.2 | -1.6 |
| EBIT, % | -1078.89 | -791.81 | -2608.97 | -2888.5 | -1239.16 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 1.3 | 11.8 | 6.2 | 1.5 | 6.6 | .6 | .8 | 1.0 | 1.2 | 1.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .3 | .3 | .2 | .2 | .2 | .4 | .5 | .6 | .8 | 1.0 |
| Account Receivables, % | 81.64 | 47.38 | 79.01 | 77.47 | 33.27 | 63.75 | 63.75 | 63.75 | 63.75 | 63.75 |
| Inventories | .1 | .0 | .0 | .0 | .0 | .1 | .1 | .1 | .1 | .2 |
| Inventories, % | 30.39 | 4.1 | 15.04 | 0 | 0 | 9.91 | 9.91 | 9.91 | 9.91 | 9.91 |
| Accounts Payable | .0 | .1 | .0 | .2 | 1.1 | .3 | .3 | .4 | .6 | .7 |
| Accounts Payable, % | 11.72 | 8.29 | 10.12 | 99.48 | 227.86 | 45.92 | 45.92 | 45.92 | 45.92 | 45.92 |
| Capital Expenditure | .0 | -.1 | -.1 | -.2 | .0 | -.2 | -.2 | -.3 | -.4 | -.5 |
| Capital Expenditure, % | -8.75 | -11 | -51.47 | -74.98 | -9.26 | -31.09 | -31.09 | -31.09 | -31.09 | -31.09 |
| Tax Rate, % | 0.22912 | 0.22912 | 0.22912 | 0.22912 | 0.22912 | 0.22912 | 0.22912 | 0.22912 | 0.22912 | 0.22912 |
| EBITAT | -4.1 | -3.4 | -6.6 | -6.5 | -5.7 | -.5 | -.7 | -.9 | -1.1 | -1.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -4.4 | -3.3 | -6.4 | -6.2 | -4.9 | -1.6 | -.7 | -.9 | -1.1 | -1.4 |
| WACC, % | 9.41 | 9.4 | 9.41 | 9.41 | 9.41 | 9.41 | 9.41 | 9.41 | 9.41 | 9.41 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -4.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1 | |||||||||
| Terminal Value | -20 | |||||||||
| Present Terminal Value | -12 | |||||||||
| Enterprise Value | -17 | |||||||||
| Net Debt | -6 | |||||||||
| Equity Value | -10 | |||||||||
| Diluted Shares Outstanding, MM | 12 | |||||||||
| Equity Value Per Share | -0.84 |
What You Will Get
- Authentic Lexaria Data: Preloaded financials – covering everything from revenue to EBIT – based on actual and projected figures.
- Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- Immediate Valuation Updates: Automatic recalculations to assess the impact of changes on Lexaria’s fair value.
- Flexible Excel Template: Designed for quick edits, scenario analysis, and detailed forecasts.
- Efficient and Precise: Bypass the hassle of building models from the ground up while ensuring accuracy and adaptability.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Lexaria Bioscience Corp. (LEXX).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to LEXX.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates as needed for Lexaria.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios pertinent to Lexaria Bioscience Corp. (LEXX).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- 1. Download the Template: Obtain and open the Excel file containing Lexaria Bioscience Corp.'s (LEXX) preloaded data.
- 2. Modify Key Inputs: Adjust critical assumptions such as growth projections, WACC, and capital investments.
- 3. Analyze Results in Real-Time: The DCF model automatically computes intrinsic value and NPV based on your inputs.
- 4. Explore Different Scenarios: Evaluate various forecasts to understand a range of valuation possibilities.
- 5. Present with Assurance: Deliver professional valuation analyses to enhance your decision-making process.
Why Choose Lexaria Bioscience Corp. (LEXX)?
- Innovation: Pioneering advancements in cannabinoid delivery technology.
- Research-Driven: Backed by extensive scientific studies and clinical trials.
- Market Potential: Positioned in a rapidly growing industry with significant opportunities.
- Experienced Leadership: Led by a team with deep expertise in biotech and pharmaceuticals.
- Commitment to Quality: Focused on high standards in product development and manufacturing.
Who Should Use This Product?
- Investors: Evaluate Lexaria Bioscience Corp.'s (LEXX) market potential before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts for Lexaria.
- Startup Founders: Understand the valuation strategies of innovative biotech companies like Lexaria.
- Consultants: Create comprehensive valuation reports tailored for clients interested in Lexaria Bioscience Corp. (LEXX).
- Students and Educators: Utilize current data to explore and teach valuation principles in the biotech sector.
What the Lexaria Bioscience Template Contains
- Preloaded LEXX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.